Drug Evaluation Central & Peripheral Nervous Systems: Tiagabine: current status and potential clinical applications

References

• JUUL-JENSEN P, FOLDSPRANG A: Natural history of epi-leptic seizures. Epilepsia (1983) 24:297–312.
   PubMed Web of Science ®Google Scholar
• SUSSMAN N, HEYDORN WE: New and investigational ▪antiepilepsy drugs. Exp. Opin. Invest. Drugs (1994) 3:355-368. An excellent overview of the new generation of antiepileptic drugs.
   Google Scholar
• KINTZER T: Nesv drug treatments in epilepsy. Eur. Neurol. (1994) 34:4–10.
   PubMed Web of Science ®Google Scholar
• KROGSGAARD-LARSEN P, FALCH E, LARSSON OM, SCHOUSBOE A: GABA uptake inhibitors: relevance to antlepileptic drug research. Epilepsy Res. (1987) 1:77-93. A comprehensive review of the interrelationships between GABA and epilepsy.
   Google Scholar
• MENGEL H: Tiagabine. Epilepsia (1994) 35\(Suppl. 5):S81–S84. 29.
   Google Scholar
• GUSTAVSON LE, MENGEL HB: Pharmacokinetics of tia- �gabine, a y-aminobutyric add-uptake inhibitor, in healthy subjects after single and multiple doses. Epilep-sia (1995) 36:605-611. An excellent review of the pharmacokinetics of tiagabine in healthy subjects.
   Google Scholar
• BRODIE MJ: Tiagabine pharmacology in profile. Epilepsia (1995) 36\(Suppl. 6):S7–9.
   Google Scholar
• GUSTAVSON LE, CATO A, GUENTHER HJ et al.: Lack of clinically important drug interactions between tia-gabine and carbamazepine, phenytoin, or valproate. Epilepsia (1995) 36\(Suppl. 3):5159.
   Google Scholar
• MENGEL H, JANSEN JA, SOMMERVILLE K et al.: Tiagabine: evaluation of the risk of interaction with theophylline, warfarin, digoxin, cimetidine, oral contraceptives, tria-zolam, or ethanoL Epilepsia (1995) 36\(Suppl. 3):S160.
   Google Scholar
• SO EL, WOLFF D, GRAVES NM et al.: Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-Inducing antlepilepsy drugs. Epilepsy Res. (1995) 22:221-226. An important reference on the pharmacokinetics of tiagabine in patients with epilepsy treated with enzyme-inducing AEDs.
   Google Scholar
• SCHACHTER SC: Tiagabine monotherapy in the treat- ment of partial epilepsy. Epilepsia (1995) 36\(Suppl. 6):S2-S6. Complete review of available monotherapy data.
   Google Scholar
• GUSTAVSON LE, QIAN JX, SAULIS R eta/.: Pharmacolcinet-ics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia (1995) 36\(Suppl. 3):S159.
   Google Scholar
• CATO A, QIAN JX, GUSTAVSON LE et al.: Pharmacokinet-ics and safety of tiagabine in subjects with various degrees of renal function. Epilepsia (1995) 36\(Suppl. 3):S159.
   Google Scholar
• SUZDAK PD, JANSEN JA: A review of the preclhlical pharmacology of tiagabine: a potent and selective anti-convulsant GABA uptake inhibitor. Epilepsia (1995) 36:612-626. Comprehensive review of preclinical pharmacology.
   Google Scholar
• MELDRUM BS: Anatomy, physiology and pathology of epilepsy. Lancet (1990) 336:320-324. Reviews the role of GABA in epilepsy.
   Google Scholar
• BRAESTRUP C, NIELSEN EB, SONNEWALD U et al.: (R)-N- [4,4-bis(3-methy1-2-thienyObut-3-en-1-yl] nipecotic acid NO-328 binds with high affinity to the brain y-ami-nobutyric add uptake carrier. J. Neurochem. (1990) 54:639–647.
   PubMedGoogle Scholar
• GIARDINA WJ: Anticonvulsant action of tiagabine, anew GABA-uptake inhibitor. J. Epilepsy (1994) 7:161–166.
   Google Scholar
• BORDEN LA, DHAR TGM, SMITH KE eta/.: Tiagabine, SK&F 89976-A, CI-966 and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur.J.Pharmacol. (1994) 269:219–224.
   Google Scholar
• RECKLING JC, JAHNSEN H, LAURSEN AM: The effect of two lipophilic GABA uptake blockers in CA1 of the rat hippocampal slice. Br. J. Pharmacol. (1990) 99:103-106. Early and important data on pharmacologic action of tiagabine.
   Google Scholar
• FINK-JENSEN A, SUZDAK P, SWEDBERG MDB et al.: The y-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur.J. Pharmacol. (1992) 220:197–201.
   PubMed Web of Science ®Google Scholar
• NIELSEN EB, SUZDAK PD, ANDERSEN KE et al.: Charac- terization of tiagabine (N0-328), a new potent and selective GABA-uptake inhibitor. Eur. J. Pharmacol. (1991) 196:257-266. Good review of early pharmacologic data of tiagabine.
   Google Scholar
• FAINGOLD CL, RANDALL ME, BOERSMA ANDERSON CA: Blockade of GABA uptake with tiagabine inhibits audio-genic seizures and reduces neuronal firing in the infe-rior colliculus of the genetically epilepsy-prone rat. E. Neurol. (1994) 126:225–232.
   PubMed Web of Science ®Google Scholar
• SUZDAK PD: rack of tolerance to the anticonvu1sant effects of tiagabine following chronk (21 day) treat-ment. Epilepsy Res. (1994) 19205–213.
   Google Scholar
• BEN-MENACHEM E: International experience with tia- gabine add-on therapy. Epilepsia (1995) 36\(Suppl. 6):S14-S21. Excellent review of efficacy of tiagabine in world-wide controlled add-on trials to date.
   Google Scholar
• SCHACHTER SC. Tiag-abine. In: Conference Review: Progress Report on New Antiepileptic Drugs. A Summary of the Third Eilat Conference. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E (Eds.) Epilepsy Res. (1996). In press. Complete overview of the clinical development of tiagabine.
   Google Scholar
• PIERCE MW, SUZDAK PD, ANDERSEN RE et al.: Tiagabine. In: New Antiepileptic Drugs. Pisani F, Perucca E, Avansini A (Eds.), Elsevier, Amsterdam (1991):157–160.
   Google Scholar
• JUDGE ME, SWEDBERG MDB, SUZDAK PD: Tolerance tothe cognitive impairing effects, but not the anticonvul-sant effects, of NO-328: a selective GABA uptake inhibi-tor. Eur. J. Pharmacol. (1990) 183:467.
   Web of Science ®Google Scholar
• Data on File. Abbott laboratories.
   Google Scholar
• Gabapenthi (Neurontine) product labeling. Physician's Desk Reference®. Medical Economics Data Production Com-pany (1995):1856–1859.
   Google Scholar
• Iamotrigine (Iamktale) product labeling. Physician's Desk Reference®. Medical Economics Data Production Com-pany (1995):A5-Al2.
   Google Scholar
• SACHDEO RC, HEARELL KM, PIXTON GC, KARDATZKE DR,SOMMERVILLE KW: Laboratory variables with tiagabine HC1 therapy. Epilepsia (1996). In press.
   Google Scholar
• SVEINBJORNSDO I rut S, SANDER JWAS, PATSALOS PN et al.: Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure (1994) 3:29–35.
   Google Scholar
• ARNETT JL, DODRILL CB, MERCANTE DE vial.: Evaluation of the effects of tiagabine HC1 on cognitive functioning and adjustment in patients with epilepsy. Epilepsia (1995) 36\(Suppl. 4):55.
   Google Scholar
• KALVIAlNEN R, AIKIA M, SAUKKONEN AM, PITKANEN A, RIEKKINEN P: Cognitive effects of tiagabine. Epilepsia (1994) 35\(Suppl. 7):74.
   Google Scholar
• DODRILL CB, ARNETT JL, MERCANTE D, LENZ, SOM-MERVILLE K: Changes in mental abilities and adjustment with conversion to tiagabine monotherapy. Neurology (1996) 46(2) A277.
   Google Scholar
• ULDALL P, BULTEAU C, PEDERSEN SA et al.: Single-blind study of safety, tolerability, and preliminary efficacy of tiagabine as adjunctive treatment of children with epi-lepsy. Epilepsia (1995) 36\(Suppl. 3):S147–S148.
   Google Scholar
• BOELLNER SW, MCCARTY J, MERCANTE D, SOMMERVILLEKW: Pilot study of tiagabine in children with partial seizures. Epilepsia (1996). In press.
   Google Scholar
• LEACH JP, BRODIE MJ: Novel antiepileptic drugs: anexplosion of activity. Seizure (1999 4:5–17.
   Google Scholar